ampelopsin has been researched along with gamma-aminobutyric acid in 1 studies
| Studies (ampelopsin) | Trials (ampelopsin) | Recent Studies (post-2010) (ampelopsin) | Studies (gamma-aminobutyric acid) | Trials (gamma-aminobutyric acid) | Recent Studies (post-2010) (gamma-aminobutyric acid) |
|---|---|---|---|---|---|
| 377 | 2 | 343 | 40,215 | 1,423 | 9,631 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Copeland, RL; Csoka, AB; Getachew, B; Manaye, KF; Tizabi, Y | 1 |
1 other study(ies) available for ampelopsin and gamma-aminobutyric acid
| Article | Year |
|---|---|
Dihydromyricetin Protects Against Salsolinol-Induced Toxicity in Dopaminergic Cell Line: Implication for Parkinson's Disease.
Topics: Cell Line, Tumor; Dopamine; Dopaminergic Neurons; gamma-Aminobutyric Acid; Humans; Neuroblastoma; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease | 2023 |